Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer

ALK-positive tumors progressing on ceritinib is not immunogenic enough to respond to immune checkpoint inhibitors. READ ARTICLE

Journal for ImmunoTherapy of Cancer DOI: 10.1136/jitc-2020-000970

Authors: Kyoung-Ho Pyo, Sun Min Lim, Chae-Won Park, Ha-Ni Jo, Jae Hwan Kim, Mi-Ran Yun, Dohee Kim, Chun-Feng Xin, Wongeun Lee, Bianca Gheorghiu, Min Hee Hong, Hye Ryun Kim, Hyo Sup Shim, Mi Jang, Sung Sook Lee, Byoung Chul Cho

Pre-ClinicalKirk SmithJune 1, 2020Pd-1 inhibitor, ceritinib